CAS: 1421783-64-3
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | GZD824 REF: AN-AG009HG2CAS: 1421783-64-3 | 98% | 188.00 €~1,007.00 € | Tue 07 May 24 |
 | Olverembatinib dimesylate REF: TM-T2429CAS: 1421783-64-3 | 100% | 39.00 €~463.00 € | Tue 14 May 24 |
 | GZD 824 REF: 3D-FG104178CAS: 1421783-64-3 | Min. 95% | To inquire | Tue 18 Jun 24 |
Ref: AN-AG009HG2
| 5mg | 188.00 € | |
| 10mg | 267.00 € | |
| 25mg | 558.00 € | |
| 50mg | 631.00 € | |
| 100mg | 1,007.00 € |
Estimated delivery in United States, on Tuesday 7 May 2024
Olverembatinib dimesylate
CAS:1421783-64-3
Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I).
Formula:
C29H27F3N6O·2CH4O3S
Purity:
100%
Color and Shape:
Solid
Molecular weight:
724.77
Ref: TM-T2429
| 1mg | 39.00 € | |
| 2mg | 56.00 € | |
| 5mg | 87.00 € | |
| 10mg | 123.00 € | |
| 25mg | 230.00 € | |
| 50mg | 317.00 € | |
| 100mg | 463.00 € | |
| 1ml*10 (DMSO) | 119.00 € |
Estimated delivery in United States, on Tuesday 14 May 2024
GZD 824
CAS:1421783-64-3
GZD 824 is a receptor molecule that competes with the receptor for the protein ubiquitin. …
Formula:
C29H27F3N6O•(CH4O3S)2
Purity:
Min. 95%
Molecular weight:
724.77 g/mol
Ref: 3D-FG104178
| 5mg | To inquire | |
| 10mg | To inquire | |
| 25mg | To inquire |
Estimated delivery in United States, on Tuesday 18 Jun 2024
